Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
Higher incidences of imAEs were observed with D+T compared with D monotherapy across tumor types; however, fatal imAEs were infrequent and similar in both datasets. ImAEs in the D+T dataset were consistent with the safety profiles of the individual agents and dual PD-(L)1 and CTLA-4 inhibition. Overall, the safety profiles of D monotherapy and D+T were tolerable and manageable across tumor types.
Authors
- Stephan Hois
- Mayur Patel (ORCID: https://orcid.org/0000-0002-9735-7211)
- Pascual Malo Concepción
- Alejandra Negro (ORCID: https://orcid.org/0000-0002-5063-9748)
- Gary J. Doherty (ORCID: https://orcid.org/0000-0002-8158-8111)
- John F. Kurland (ORCID: https://orcid.org/0000-0003-0863-2486)
- Cathy O’Brien
- Dejan Pavlović
- K. Thomas Robbins
- Claire Morgan
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Spain) (ES)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-011140
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14